Pharmaceuticals Sandoz continues to grow thanks to strong biosimilars
The generics specialist Sandoz continued to grow last year. The Group met both its own and analysts' expectations. The current year is expected to continue at a similar pace.
25.02.2026, 07:35
SDA
As Sandoz announced on Wednesday, revenues climbed to 11.1 billion US dollars, an increase of 7 percent. At constant exchange rates, the increase was 5 percent, which means that the former Novartis subsidiary met its own target of growth at constant exchange rates in the mid-single-digit percentage range.
Of the two divisions, the generics business contributed 7.8 billion dollars to total sales and thus grew by 2 percent at constant exchange rates. Revenue increased slightly in almost all regions. In North America, they remained at the previous year's level in the face of tough competition, according to the press release.
The smaller biosimilars division improved its turnover by 13 percent to 3.3 billion dollars. The most recent launches in particular boosted business considerably. Overall, biosimilars contributed 30 percent to Group sales, which means that Sandoz has already achieved one of its medium-term targets.
Significantly higher profit
At the profit level, Sandoz reported core operating profit (core EBITDA) of USD 2.4 billion (+14%). The corresponding margin amounted to 21.7% after 20.1% in the previous year.
At the bottom line, net profit shot up by a third to 1.6 billion dollars. Sandoz attributes the significant increase to the growth in core operating profit and a decline in operating income taxes.
For the current financial year, the Basel-based company is forecasting similar growth as before: net sales are expected to grow in the mid to high single-digit range and the core EBITDA margin is expected to increase by around 1 percentage point in 2026.
